Anavex Life Sciences recently announced promising results from a 48-week Phase 2 extension study evaluating their lead drug candidate, ANAVEX®2-73, for Parkinson’s disease dementia. The study successfully met both its primary and secondary objectives, indicating potential efficacy in managing this debilitating condition. In the course of the study, ANAVEX®2-73 exhibited a favorable safety profile and […]
More .... Anavex Life Sciences Announces Positive Findings in Parkinson’s Disease Dementia Study